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Screening in Medullary Thyroid Carcinoma
C. Calmettes*

The four-year experience ofthe French collaborative study on medullary thyroid carcinoma (MTC)
has permitted improvement in family screening by a common discussion of data and a network of
coordinators throughout France involved in the detection of new cases. Investigations have been
directed at improving the discrimination between sporadic and hereditary forms ofMTC and between
individuals who have or have not inherited the disease within families. (Henry Ford Hosp MedJ
1987:35:99-100)

M

ost clinicians lack experience in handling cases of medullary thyroid carcinoma (MTC); these tumors are not only
rare but also difficult to manage. The French medullary thyroid
study group was created in 1982 to collaboratively support research on the disease and to help physicians caring for patients
with MTC. A common protocol was established for patient management and for screening within families. Specialized study
groups, a central registry of cases, and a network of regional
coordinators were created to collect and analyze data.

Tools for Screening
Thefirstobjective of the group was to test the various tools for
MTC screening. Since the diagnosis depends on calcitonin (CT)
assay (1) and/or pathological examination, the efficacy ofthese
techniques was analyzed and the network of coordinators was
organized to study family members throughout France.
CT assay
A comparison of the different assay methods used in France
confirmed and provided several conclusions:
1. Artifacts can be excluded by means of serial dilutions ofthe
plasma and the use of pentagastrin-stimulated CT test, which
also allows discrimination between elevations of CT of thyroid
or of ectopic origin (2).
2. Any technique provides good results when the basal CT
level is high, but variations in normal values obtained by
different assays must be appreciated (3), and at times it is useful to have duplicate aliquots assayed in different immunoassay systems.
3. The pentagastrin-stimulated CT test is efficient in early detection of MTC, but the upper limits of normal must be known
for the particular assay used. This provocative test must be performed in all cases of family screening, though an upper age
limit needs to be determined [MTC can be still very small even
after age 60 (4), as also observed in cases of our group]. This
procedure also eliminates artifacts found in using basal CT
levels only (5).
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Pathology
Realizing the benefits of CT and thyroglobulin (Tg) immunopathological studies in the diagnosis of the type of thyroid
cancer (6), these studies were performed in specialized laboratories. The use of these techniques allowed confirmation of the
diagnosis of MTC and an estimation of C-cell hyperplasia. Interestingly, this allowed recognition of atypical MTC, especially
those with a trabecular, follicular (7), or papillary pattem, or Tgsecreting carcinoma with amyloidosis mimicking MTC.

Research on Criteria for Diagnosing Hereditary
Forms of MTC
Efforts of the group have been directed toward determining
the criteria by which the hereditary form of MTC can be differentiated from the sporadic form. If screening efforts can be concentrated to the families of those with the hereditary disease,
much effort of screening can be saved and the costs decreased.
Family screening
Clinical screening may not always discriminate between the
hereditary and sporadic forms of MTC because of unknown parentage, a limited number of available relatives, lack of family
cooperation, and lack of knowledge of the type of cancer or thyroid disease in family members.
Utilizing CT assay within families has limitations since it is
not always possible to test enough family members to establish
whether or not the disease is hereditary or sporadic.
Pathology
In our collaborative study, over 190 MTC cases have been
collected, with most cases reviewed by ten histopathologists
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(8). Cancers and/or C-cell hyperplasia are bilateral in hereditary
MTC but also may occur, in our experience, in the sporadic
form. Preliminary results suggest that a cancer limited to only
one lobe of the thyroid gland without evident C-cell hyperplasia
is a feature of the sporadic form only if adequate sections of the
thyroid are available for study.

The evolution of MTC is quite variable in both the sporadic
and hereditary form. Even though the prognosis generally
appears better in the hereditary form, the tumors are very
aggressive in some of these cases.

Endocrinology
Studies have been carried out for ACTH, P-lipotropin, endorphin, somatostatin (9-11), and CT-gene-related-peptide in
plasma and in tumors. The increase in plasma of P-lipotropin
seems to be more frequent in the hereditary form and of
somatostatin in the sporadic form.
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HLA determination
No linkage was observed between MTC and HLA type in several families as presented in Cambridge by Guillausseau et al
(12) and as reported by Simpson and Falk (13).
Meta-iodo-benzylguanidine (MIBG) scintigraphy
The results of the study of more than 50 cases have led
Baulieu et al (14) to conclude that MIBG uptake in MTC is usually a feature of hereditary MTC.
In summary, no technique has yet been able to discriminate
between the hereditary and the sporadic form of MTC in all
cases. Unfortunately, repetitive screening of family members
remains necessary despite its difficulties.

Results of Screening for MTC in France
Although the registry was established in 1970, the common
protocol was established only four years ago. The registry
includes nearly 1,000 cases, with a high likelihood that 175
cases are sporadic cases (based on extensive family screening
and pathological criteria) and with 206 cases hereditary in 59
families. In the past two years, one-half of the new cases have
been hereditary.
The hereditary cases appear to be isolated MTC in 29 families
without other components of MEN-2 syndromes, MEN-2A in
26 families and a few cases of the MEN-2B phenotype. The
gene has a variable expression in MEN-2 even within the same
family, with pheochromocytomas in 40% to 45% and parathyroid tumors in 16% to 18% of cases at thetimeof screening.
The origin from the west of France (16 families) or Mediterranean area (13 families, eight of which are foreign) should make
interesting genealogic studies. The registry has permitted cases
to be linked from different family branches.
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